Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Total Liabilities over the past 14 years, most recently at $153.0 million for Q1 2026.

  • For Q1 2026, Total Liabilities rose 170.77% year-over-year to $153.0 million; the TTM value through Mar 2026 reached $153.0 million, up 170.77%, while the annual FY2025 figure was $177.3 million, 150.48% up from the prior year.
  • Total Liabilities for Q1 2026 was $153.0 million at Viridian Therapeutics, Inc.\DE, down from $177.3 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $177.3 million in Q4 2025 and troughed at $16.5 million in Q1 2022.
  • A 5-year average of $61.7 million and a median of $48.4 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: decreased 1.85% in 2022 and later surged 170.77% in 2026.
  • Year by year, Total Liabilities stood at $40.0 million in 2022, then increased by 20.92% to $48.4 million in 2023, then soared by 46.2% to $70.8 million in 2024, then soared by 150.48% to $177.3 million in 2025, then fell by 13.68% to $153.0 million in 2026.
  • Business Quant data shows Total Liabilities for VRDN at $153.0 million in Q1 2026, $177.3 million in Q4 2025, and $74.2 million in Q3 2025.